Beam Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference
02 8월 2022 - 9:30PM
Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company
developing precision genetic medicines through base editing, today
announced that John Evans, chief executive officer, will
participate in a panel titled, “So Let it Be (Re)Written - Updates
in Gene Modulation” during the 2022 Wedbush PacGrow Virtual
Healthcare Conference on Tuesday, August 9, 2022 at 9:45 a.m. ET.
A live webcast will be available in the investor
section of the company's website at www.beamtx.com, and will be
archived for 60 days following the presentation.
About Beam TherapeuticsBeam
Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to
establishing the leading, fully integrated platform for precision
genetic medicines. To achieve this vision, Beam has assembled a
platform that includes a suite of gene editing and delivery
technologies and is in the process of building internal
manufacturing capabilities. Beam’s suite of gene editing
technologies is anchored by base editing, a proprietary technology
that is designed to enable precise, predictable and efficient
single base changes, at targeted genomic sequences, without making
double-stranded breaks in the DNA. This has the potential to enable
a wide range of potential therapeutic editing strategies that Beam
is using to advance a diversified portfolio of base editing
programs. Beam is a values-driven organization committed to its
people, cutting-edge science, and a vision of providing life-long
cures to patients suffering from serious diseases.
Contacts:
Investors:Chelcie ListerTHRUST Strategic
Communicationschelcie@thrustsc.com
Media:Dan Budwick1ABdan@1abmedia.com
Beam Therapeutics (NASDAQ:BEAM)
과거 데이터 주식 차트
부터 8월(8) 2024 으로 9월(9) 2024
Beam Therapeutics (NASDAQ:BEAM)
과거 데이터 주식 차트
부터 9월(9) 2023 으로 9월(9) 2024